16-h fasting optimizes cancer immunotherapy in mice and humans - PubMed
2 days ago
- #immunometabolism
- #dietary intervention
- #cancer immunotherapy
- A 16-hour fasting regimen enhances the efficacy of cancer immunotherapy in both mice and humans.
- Short-term fasting alters tumor-cell nutrient preferences, creating a metabolic window to improve treatment.
- Fasting induces intratumoral accumulation of isoleucine, which enhances CD8+ T cell anti-tumor capacity through epigenetic and phospholipid remodeling.
- In human patients, short-term fasting boosted CD8+ T cell clonal expansion and cytotoxic programs during neoadjuvant immunotherapy.
- This dietary intervention is clinically feasible, well-tolerated, and counters nutrient competition in the tumor microenvironment.